Table 3.

Clinical characteristics of the patients (n = 20).

Variable	Total n (%)	Severe group n (%)	Non-severe group n (%)	P-value
Immunization history
Yes	1 (5%)	0	1 (16.7%)	0.30
No	19 (95)	14 (100%)	5 (83.3%)
Postexposure prophylaxis				1.0
Yes	1 (5%)	1 (7.1%)	0
No	19 (95)	13 (92.9%)	6 (100%)
Wound type				0.30
Puncture	13 (65%)	11 (78.6%)	3 (50%)
Other injury type	6 (30%)	3 (21.4%)	3 (50%)
Location of wound				0.27
Upper limbs	5 (25%)	4 (28.6%)	1 (16.7)
Lower limbs	14 (70%)	10 (71.4%)	4 (66.7%)
Not identified	1 (5%)	0	1 (16.7%)
Wound cleaning before admission				1.0
Yes	3 (15%)	2 (14.3%)	1 (16.7%)
No	17 (85%)	12 (85.7%)	5 (83.3%)
First clinical symptoms
Lockjaw	16 (80%)	14 (100%)	2 (33.3%)	0.80
Snarling smile	17 (85%)	14 (100%)	3 (50%)
Muscle spasm	11 (55%)	10 (71.4%)	1 (16.7%)
First diagnosis correctly
Yes	17 (85%)	13 (92.9%)	4 (66.7%)	0.20
No	3 (15%)	1 (7.1%)	2 (33.3%)
Autonomic instability				0.0002
Yes	13 (65%)	13 (92.9%)	0
No	7 (35%)	1 (7.1%)	6 (100%)
Comorbidity.				0.77
Hypertension	3 (15%)	3 (%)	1 (%)
Diabetes mellitus,	2 (10%)	2 (%)	0
COPD	1 (5%)	1 (%)	0
Ischemic heart disease	1 (5%)	1 (%)	0
Onset time (days)				0.16
< 2	11 (55%)	10 (71.4%)	2 (33.3%)
≥2	9 (45%)	4 (28.6%)	4 (66.7%)
Incubation period (days), median (IQR)	8 (3–15)	7.5 (5–12)	12 (3–15)	0.21
APACHE-II at day 0, median (IQR)	13.5 (11–18).	14 (12–18)	13 (11–15)	0.16